The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?

Zweig, J; Wakelee, H

Wakelee, H (reprint author), Stanford Univ, Div Oncol, Dept Med, 875 Blake Wilbur Dr, Stanford, CA 94305 USA.

AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2017; 13 (9): 32

Abstract

Therapeutic options for advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer have changed dramatically since the 2011 approva......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索